Difference between revisions of "Volunteer Assignments and Opportunities"

From Compendium of Cancer Genome Aberrations
Jump to navigation Jump to search
VisualWikitext
[unchecked revision][unchecked revision]
Line 4: Line 4:
 
|-
 
|-
 
!'''Disease'''!!'''Page Type'''!!'''Author'''
 
!'''Disease'''!!'''Page Type'''!!'''Author'''
−
!'''Date Assigned (Target Page Completion Date)'''!!'''Associate Editor'''
+
!'''Date Assigned to Author (Target Completion Date)'''!!'''Associate Editor'''
−
!Author Content Pending or Complete (Date Completed)
+
!'''Author Content Pending or Complete (Date Completed)'''
−
!Editor Reviewed (Date)
+
!'''Date Completed by Author'''
−
!Notes
+
!'''Editor Reviewed (Date of Last Review)'''
 +
!'''Notes'''
 
|-
 
|-
 
|'''''Myeloproliferative Neoplasms (MPN)'''''||'''''Overview'''''||Mark Evans (trainee), Fabiola Quintero-Rivera
 
|'''''Myeloproliferative Neoplasms (MPN)'''''||'''''Overview'''''||Mark Evans (trainee), Fabiola Quintero-Rivera
Line 13: Line 14:
 
|Fabiola Quintero-Rivera (FQR)
 
|Fabiola Quintero-Rivera (FQR)
 
|PENDING
 
|PENDING
 +
|
 
|
 
|
 
|
 
|
Line 21: Line 23:
 
|FQR
 
|FQR
 
|Complete
 
|Complete
 +
|
 
|
 
|
 
|
 
|
Line 29: Line 32:
 
|FQR
 
|FQR
 
|PENDING
 
|PENDING
 +
|
 
|
 
|
 
|
 
|
Line 37: Line 41:
 
|FQR
 
|FQR
 
|PENDING
 
|PENDING
 +
|
 
|
 
|
 
|
 
|
Line 45: Line 50:
 
|FQR
 
|FQR
 
|PENDING
 
|PENDING
 +
|
 
|
 
|
 
|
 
|
Line 53: Line 59:
 
|FQR
 
|FQR
 
|PENDING
 
|PENDING
 +
|
 
|
 
|
 
|
 
|
Line 61: Line 68:
 
|FQR
 
|FQR
 
|PENDING
 
|PENDING
 +
|
 
|
 
|
 
|
 
|
Line 69: Line 77:
 
|FQR
 
|FQR
 
|PENDING
 
|PENDING
 +
|
 
|
 
|
 
|
 
|
Line 74: Line 83:
 
|'''''Mastocytosis'''''||'''''Overview'''''||
 
|'''''Mastocytosis'''''||'''''Overview'''''||
 
| ||FQR
 
| ||FQR
 +
|
 
|
 
|
 
|
 
|
Line 83: Line 93:
 
|FQR
 
|FQR
 
|PENDING
 
|PENDING
 +
|
 
|
 
|
 
|
 
|
Line 91: Line 102:
 
|FQR
 
|FQR
 
|PENDING
 
|PENDING
 +
|
 
|
 
|
 
|
 
|
Line 99: Line 111:
 
|FQR
 
|FQR
 
|PENDING
 
|PENDING
 +
|
 
|
 
|
 
|
 
|
Line 106: Line 119:
 
|FQR
 
|FQR
 
|PENDING
 
|PENDING
 +
|
 
|
 
|
 
|
 
|
Line 113: Line 127:
 
|FQR
 
|FQR
 
|Complete
 
|Complete
 +
|
 
|
 
|
 
|
 
|
Line 120: Line 135:
 
|FQR
 
|FQR
 
|Complete
 
|Complete
 +
|
 
|
 
|
 
|
 
|
Line 127: Line 143:
 
|FQR
 
|FQR
 
|Complete
 
|Complete
 +
|
 
|
 
|
 
|
 
|
Line 134: Line 151:
 
|FQR
 
|FQR
 
|Complete
 
|Complete
 +
|
 
|
 
|
 
|
 
|
Line 143: Line 161:
 
|FQR
 
|FQR
 
|Complete
 
|Complete
 +
|
 
|
 
|
 
|NON-WHO ENTITY
 
|NON-WHO ENTITY
Line 152: Line 171:
 
|FQR
 
|FQR
 
|Complete
 
|Complete
 +
|
 
|
 
|
 
|NON-WHO ENTITY
 
|NON-WHO ENTITY
Line 159: Line 179:
 
|FQR
 
|FQR
 
|Complete
 
|Complete
 +
|
 
|
 
|
 
|
 
|
Line 166: Line 187:
 
|FQR
 
|FQR
 
|Complete
 
|Complete
 +
|
 
|
 
|
 
|
 
|
Line 173: Line 195:
 
|FQR
 
|FQR
 
|Complete
 
|Complete
 +
|
 
|
 
|
 
|
 
|
Line 180: Line 203:
 
|FQR
 
|FQR
 
|PENDING
 
|PENDING
 +
|
 
|
 
|
 
|
 
|
Line 187: Line 211:
 
|FQR
 
|FQR
 
|PENDING
 
|PENDING
 +
|
 
|
 
|
 
|
 
|
Line 194: Line 219:
 
|FQR
 
|FQR
 
|PENDING
 
|PENDING
 +
|
 
|
 
|
 
|
 
|
Line 200: Line 226:
 
|
 
|
 
|FQR
 
|FQR
 +
|
 
|
 
|
 
|
 
|
Line 208: Line 235:
 
|FQR
 
|FQR
 
|PENDING
 
|PENDING
 +
|
 
|
 
|
 
|
 
|
Line 215: Line 243:
 
|FQR
 
|FQR
 
|Complete
 
|Complete
 +
|
 
|
 
|
 
|
 
|
Line 222: Line 251:
 
|FQR
 
|FQR
 
|Complete
 
|Complete
 +
|
 
|
 
|
 
|
 
|
Line 229: Line 259:
 
|FQR
 
|FQR
 
|PENDING
 
|PENDING
 +
|
 
|
 
|
 
|
 
|
Line 236: Line 267:
 
|FQR
 
|FQR
 
|PENDING
 
|PENDING
 +
|
 
|
 
|
 
|
 
|
Line 243: Line 275:
 
|FQR
 
|FQR
 
|Complete
 
|Complete
 +
|
 
|
 
|
 
|
 
|
Line 250: Line 283:
 
|FQR
 
|FQR
 
|PENDING
 
|PENDING
 +
|
 
|
 
|
 
|
 
|
Line 257: Line 291:
 
|FQR
 
|FQR
 
|PENDING
 
|PENDING
 +
|
 
|
 
|
 
|
 
|
Line 262: Line 297:
 
| || ||
 
| || ||
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 270: Line 306:
 
|Jennelle Hodge (JH)/ Malini Sathanoori (MS)
 
|Jennelle Hodge (JH)/ Malini Sathanoori (MS)
 
|Complete
 
|Complete
 +
|
 
|
 
|
 
|
 
|
Line 276: Line 313:
 
| ||JH / MS
 
| ||JH / MS
 
|Complete
 
|Complete
 +
|
 
|
 
|
 
|
 
|
Line 282: Line 320:
 
| ||JH / MS
 
| ||JH / MS
 
|PENDING
 
|PENDING
 +
|
 
|
 
|
 
|
 
|
Line 288: Line 327:
 
| ||JH / MS
 
| ||JH / MS
 
|PENDING
 
|PENDING
 +
|
 
|
 
|
 
|
 
|
Line 294: Line 334:
 
| ||JH / MS
 
| ||JH / MS
 
|PENDING
 
|PENDING
 +
|
 
|
 
|
 
|
 
|
Line 300: Line 341:
 
| ||JH / MS
 
| ||JH / MS
 
|PENDING
 
|PENDING
 +
|
 
|
 
|
 
|
 
|
Line 306: Line 348:
 
| ||JH / MS
 
| ||JH / MS
 
|Complete
 
|Complete
 +
|
 
|
 
|
 
|
 
|
Line 312: Line 355:
 
| ||JH / MS
 
| ||JH / MS
 
|Complete
 
|Complete
 +
|
 
|
 
|
 
|
 
|
Line 319: Line 363:
 
|JH / MS
 
|JH / MS
 
|Complete
 
|Complete
 +
|
 
|
 
|
 
|
 
|
Line 325: Line 370:
 
| ||JH / MS
 
| ||JH / MS
 
|Complete
 
|Complete
 +
|
 
|
 
|
 
|
 
|
Line 331: Line 377:
 
| ||JH / MS
 
| ||JH / MS
 
|Complete
 
|Complete
 +
|
 
|
 
|
 
|
 
|
Line 337: Line 384:
 
| ||JH / MS
 
| ||JH / MS
 
|Complete
 
|Complete
 +
|
 
|
 
|
 
|
 
|
Line 343: Line 391:
 
| ||JH / MS
 
| ||JH / MS
 
|Complete
 
|Complete
 +
|
 
|
 
|
 
|
 
|
Line 349: Line 398:
 
| ||JH / MS
 
| ||JH / MS
 
|Complete
 
|Complete
 +
|
 
|
 
|
 
|
 
|
Line 355: Line 405:
 
| ||JH / MS
 
| ||JH / MS
 
|Complete
 
|Complete
 +
|
 
|
 
|
 
|Need permission for figure?  Update WHO?
 
|Need permission for figure?  Update WHO?
Line 361: Line 412:
 
| ||JH / MS
 
| ||JH / MS
 
|Complete
 
|Complete
 +
|
 
|
 
|
 
|
 
|
Line 367: Line 419:
 
| ||JH / MS
 
| ||JH / MS
 
|Complete
 
|Complete
 +
|
 
|
 
|
 
|
 
|
Line 373: Line 426:
 
| ||JH / MS
 
| ||JH / MS
 
|Complete
 
|Complete
 +
|
 
|
 
|
 
|Add WHO reference
 
|Add WHO reference
Line 379: Line 433:
 
| ||JH / MS
 
| ||JH / MS
 
|Complete
 
|Complete
 +
|
 
|
 
|
 
|
 
|
Line 385: Line 440:
 
| ||JH / MS
 
| ||JH / MS
 
|Complete
 
|Complete
 +
|
 
|
 
|
 
|
 
|
Line 391: Line 447:
 
| ||JH / MS
 
| ||JH / MS
 
|Complete
 
|Complete
 +
|
 
|
 
|
 
|
 
|
Line 397: Line 454:
 
| ||JH / MS
 
| ||JH / MS
 
|Complete
 
|Complete
 +
|
 
|
 
|
 
|Check reference format
 
|Check reference format
Line 403: Line 461:
 
| ||JH / MS
 
| ||JH / MS
 
|Complete
 
|Complete
 +
|
 
|
 
|
 
|
 
|
Line 409: Line 468:
 
| ||JH / MS
 
| ||JH / MS
 
|Complete
 
|Complete
 +
|
 
|
 
|
 
|
 
|
Line 415: Line 475:
 
| ||JH / MS
 
| ||JH / MS
 
|Complete
 
|Complete
 +
|
 
|
 
|
 
|
 
|
Line 421: Line 482:
 
| ||JH / MS
 
| ||JH / MS
 
|Complete
 
|Complete
 +
|
 
|
 
|
 
|
 
|
Line 427: Line 489:
 
| ||JH / MS
 
| ||JH / MS
 
|Complete
 
|Complete
 +
|
 
|
 
|
 
|
 
|
Line 433: Line 496:
 
| ||JH / MS
 
| ||JH / MS
 
|Complete
 
|Complete
 +
|
 
|
 
|
 
|
 
|
Line 439: Line 503:
 
| ||JH / MS
 
| ||JH / MS
 
|Complete
 
|Complete
 +
|
 
|
 
|
 
|
 
|
Line 445: Line 510:
 
| ||JH / MS
 
| ||JH / MS
 
|Complete
 
|Complete
 +
|
 
|
 
|
 
|
 
|
Line 451: Line 517:
 
| ||JH / MS
 
| ||JH / MS
 
|Complete
 
|Complete
 +
|
 
|
 
|
 
|
 
|
Line 457: Line 524:
 
| ||JH / MS
 
| ||JH / MS
 
|Complete
 
|Complete
 +
|
 
|
 
|
 
|
 
|
Line 463: Line 531:
 
| ||JH / MS
 
| ||JH / MS
 
|Complete
 
|Complete
 +
|
 
|
 
|
 
|
 
|
Line 469: Line 538:
 
| ||JH / MS
 
| ||JH / MS
 
|Complete
 
|Complete
 +
|
 
|
 
|
 
|Need permission for figure?
 
|Need permission for figure?
Line 475: Line 545:
 
| ||JH / MS
 
| ||JH / MS
 
|Complete
 
|Complete
 +
|
 
|
 
|
 
|
 
|
Line 481: Line 552:
 
| ||JH / MS
 
| ||JH / MS
 
|Complete
 
|Complete
 +
|
 
|
 
|
 
|
 
|
Line 487: Line 559:
 
| ||JH / MS
 
| ||JH / MS
 
|Complete
 
|Complete
 +
|
 
|
 
|
 
|
 
|
Line 493: Line 566:
 
| ||JH / MS
 
| ||JH / MS
 
|Complete
 
|Complete
 +
|
 
|
 
|
 
|
 
|
Line 499: Line 573:
 
| ||JH / MS
 
| ||JH / MS
 
|Complete
 
|Complete
 +
|
 
|
 
|
 
|Check reference format
 
|Check reference format
Line 505: Line 580:
 
| ||JH / MS
 
| ||JH / MS
 
|Complete
 
|Complete
 +
|
 
|
 
|
 
|
 
|
Line 511: Line 587:
 
| ||JH / MS
 
| ||JH / MS
 
|Complete
 
|Complete
 +
|
 
|
 
|
 
|
 
|
Line 517: Line 594:
 
| ||JH / MS
 
| ||JH / MS
 
|Complete
 
|Complete
 +
|
 
|
 
|
 
|Check reference format
 
|Check reference format
Line 523: Line 601:
 
| ||JH / MS
 
| ||JH / MS
 
|Complete
 
|Complete
 +
|
 
|
 
|
 
|
 
|
Line 529: Line 608:
 
| ||JH / MS
 
| ||JH / MS
 
|??
 
|??
 +
|
 
|
 
|
 
|
 
|
Line 535: Line 615:
 
| ||JH / MS
 
| ||JH / MS
 
|??
 
|??
 +
|
 
|
 
|
 
|
 
|
Line 544: Line 625:
 
|JH / MS
 
|JH / MS
 
|Complete
 
|Complete
 +
|
 
|
 
|
 
|NON-WHO ENTITY
 
|NON-WHO ENTITY
Line 553: Line 635:
 
|JH / MS
 
|JH / MS
 
|PENDING
 
|PENDING
 +
|
 
|
 
|
 
|NON-WHO ENTITY
 
|NON-WHO ENTITY
Line 562: Line 645:
 
|JH / MS
 
|JH / MS
 
|PENDING
 
|PENDING
 +
|
 
|
 
|
 
|NON-WHO ENTITY
 
|NON-WHO ENTITY
Line 567: Line 651:
 
| || ||
 
| || ||
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 573: Line 658:
 
|'''''Precursor Lymphoid Neoplasms'''''||'''''Overview'''''||
 
|'''''Precursor Lymphoid Neoplasms'''''||'''''Overview'''''||
 
| ||Yassmine Akkari (YA)
 
| ||Yassmine Akkari (YA)
 +
|
 
|
 
|
 
|
 
|
Line 579: Line 665:
 
|'''''B-Lymphoblastic Leukemia/Lymphoma with Recurrent Genetic  Abnormalities'''''||'''''Overview'''''||
 
|'''''B-Lymphoblastic Leukemia/Lymphoma with Recurrent Genetic  Abnormalities'''''||'''''Overview'''''||
 
| ||YA
 
| ||YA
 +
|
 
|
 
|
 
|
 
|
Line 585: Line 672:
 
|    B-Lymphoblastic  Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1    ||Disease||
 
|    B-Lymphoblastic  Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1    ||Disease||
 
| ||YA
 
| ||YA
 +
|
 
|
 
|
 
|
 
|
Line 593: Line 681:
 
|YA
 
|YA
 
|PENDING
 
|PENDING
 +
|
 
|
 
|
 
|
 
|
Line 598: Line 687:
 
|    B-Lymphoblastic Leukemia/Lymphoma with  t(12;21)(p13.2;q22.1); ETV6-RUNX1||Disease||
 
|    B-Lymphoblastic Leukemia/Lymphoma with  t(12;21)(p13.2;q22.1); ETV6-RUNX1||Disease||
 
| ||YA
 
| ||YA
 +
|
 
|
 
|
 
|
 
|
Line 604: Line 694:
 
|    B-Lymphoblastic Leukemia/Lymphoma with  Hyperdiploidy||Disease||
 
|    B-Lymphoblastic Leukemia/Lymphoma with  Hyperdiploidy||Disease||
 
| ||YA
 
| ||YA
 +
|
 
|
 
|
 
|
 
|
Line 614: Line 705:
 
|YA
 
|YA
 
|Complete
 
|Complete
 +
|
 
|
 
|
 
|
 
|
Line 619: Line 711:
 
|    B-Lymphoblastic Leukemia/Lymphoma with  t(5;14)(q31.1;q32.1); IGH/IL3||Disease||
 
|    B-Lymphoblastic Leukemia/Lymphoma with  t(5;14)(q31.1;q32.1); IGH/IL3||Disease||
 
| ||YA
 
| ||YA
 +
|
 
|
 
|
 
|
 
|
Line 625: Line 718:
 
|    B-Lymphoblastic Leukemia/Lymphoma with  t(1;19)(q23;p13.3); TCF3-PBX1||Disease||
 
|    B-Lymphoblastic Leukemia/Lymphoma with  t(1;19)(q23;p13.3); TCF3-PBX1||Disease||
 
| ||YA
 
| ||YA
 +
|
 
|
 
|
 
|
 
|
Line 633: Line 727:
 
|YA
 
|YA
 
|Complete
 
|Complete
 +
|
 
|
 
|
 
|
 
|
Line 638: Line 733:
 
|    B-Lymphoblastic Leukemia/Lymphoma with  iAMP21||Disease||
 
|    B-Lymphoblastic Leukemia/Lymphoma with  iAMP21||Disease||
 
| ||YA
 
| ||YA
 +
|
 
|
 
|
 
|
 
|
Line 644: Line 740:
 
|    B-Lymphoblastic Leukemia/Lymphoma, Not  Otherwise Specified||Disease||
 
|    B-Lymphoblastic Leukemia/Lymphoma, Not  Otherwise Specified||Disease||
 
| ||YA
 
| ||YA
 +
|
 
|
 
|
 
|
 
|
Line 650: Line 747:
 
|'''''T-Lymphoblastic Leukemia/Lymphoma'''''||'''''Overview'''''||
 
|'''''T-Lymphoblastic Leukemia/Lymphoma'''''||'''''Overview'''''||
 
| ||YA
 
| ||YA
 +
|
 
|
 
|
 
|
 
|
Line 656: Line 754:
 
|Early T-Cell Precursor Lymphoblastic Leukemia||Disease||
 
|Early T-Cell Precursor Lymphoblastic Leukemia||Disease||
 
| ||YA
 
| ||YA
 +
|
 
|
 
|
 
|
 
|
Line 662: Line 761:
 
|NK-Lymphoblastic Leukemia/Lymphoma||Disease||
 
|NK-Lymphoblastic Leukemia/Lymphoma||Disease||
 
| ||YA
 
| ||YA
 +
|
 
|
 
|
 
|
 
|
Line 672: Line 772:
 
|YA
 
|YA
 
|PENDING
 
|PENDING
 +
|
 
|
 
|
 
|NON-WHO ENTITY
 
|NON-WHO ENTITY
Line 677: Line 778:
 
| || ||
 
| || ||
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 683: Line 785:
 
|'''''Mature B-Cell Neoplasms'''''||'''''Overview'''''||
 
|'''''Mature B-Cell Neoplasms'''''||'''''Overview'''''||
 
| ||Snehal Patel (SP)
 
| ||Snehal Patel (SP)
 +
|
 
|
 
|
 
|
 
|
Line 691: Line 794:
 
|SP
 
|SP
 
|PENDING
 
|PENDING
 +
|
 
|
 
|
 
|
 
|
Line 698: Line 802:
 
|SP
 
|SP
 
|PENDING
 
|PENDING
 +
|
 
|
 
|
 
|
 
|
Line 705: Line 810:
 
|SP
 
|SP
 
|PENDING
 
|PENDING
 +
|
 
|
 
|
 
|
 
|
Line 712: Line 818:
 
|SP
 
|SP
 
|Complete
 
|Complete
 +
|
 
|
 
|
 
|Malini to review
 
|Malini to review
Line 719: Line 826:
 
|SP
 
|SP
 
|Complete
 
|Complete
 +
|
 
|
 
|
 
|Malini to review
 
|Malini to review
Line 726: Line 834:
 
|SP
 
|SP
 
|Complete
 
|Complete
 +
|
 
|
 
|
 
|Malini to review
 
|Malini to review
Line 733: Line 842:
 
|SP
 
|SP
 
|Complete
 
|Complete
 +
|
 
|
 
|
 
|Malini to review
 
|Malini to review
Line 740: Line 850:
 
|SP
 
|SP
 
|Complete
 
|Complete
 +
|
 
|
 
|
 
|Malini to review
 
|Malini to review
Line 747: Line 858:
 
|SP
 
|SP
 
|PENDING
 
|PENDING
 +
|
 
|
 
|
 
|
 
|
Line 754: Line 866:
 
|SP
 
|SP
 
|PENDING
 
|PENDING
 +
|
 
|
 
|
 
|
 
|
Line 759: Line 872:
 
|IgM Monoclonal Gammopathy of Undetermined Significance||Disease||
 
|IgM Monoclonal Gammopathy of Undetermined Significance||Disease||
 
| ||SP
 
| ||SP
 +
|
 
|
 
|
 
|
 
|
Line 765: Line 879:
 
|'''''Heavy Chain Diseases'''''||'''''Overview'''''||
 
|'''''Heavy Chain Diseases'''''||'''''Overview'''''||
 
| ||SP
 
| ||SP
 +
|
 
|
 
|
 
|
 
|
Line 771: Line 886:
 
|    Mu Heavy Chain  Disease||Disease||
 
|    Mu Heavy Chain  Disease||Disease||
 
| ||SP
 
| ||SP
 +
|
 
|
 
|
 
|
 
|
Line 777: Line 893:
 
|   Gamma Heavy Chain  Disease||Disease||
 
|   Gamma Heavy Chain  Disease||Disease||
 
| ||SP
 
| ||SP
 +
|
 
|
 
|
 
|
 
|
Line 783: Line 900:
 
|    Alpha Heavy Chain  Disease||Disease||
 
|    Alpha Heavy Chain  Disease||Disease||
 
| ||SP
 
| ||SP
 +
|
 
|
 
|
 
|
 
|
Line 791: Line 909:
 
|SP
 
|SP
 
|PENDING
 
|PENDING
 +
|
 
|
 
|
 
|
 
|
Line 798: Line 917:
 
|SP
 
|SP
 
|PENDING
 
|PENDING
 +
|
 
|
 
|
 
|
 
|
Line 805: Line 925:
 
|SP
 
|SP
 
|PENDING
 
|PENDING
 +
|
 
|
 
|
 
|
 
|
Line 812: Line 933:
 
|SP
 
|SP
 
|PENDING
 
|PENDING
 +
|
 
|
 
|
 
|
 
|
Line 819: Line 941:
 
|SP
 
|SP
 
|PENDING
 
|PENDING
 +
|
 
|
 
|
 
|
 
|
Line 824: Line 947:
 
|'''''    Monoclonal  Immunoglobulin Deposition Diseases'''''||'''''Overview'''''||
 
|'''''    Monoclonal  Immunoglobulin Deposition Diseases'''''||'''''Overview'''''||
 
| ||SP
 
| ||SP
 +
|
 
|
 
|
 
|
 
|
Line 830: Line 954:
 
|           Primary  Amyloidosis||Disease||
 
|           Primary  Amyloidosis||Disease||
 
| ||SP
 
| ||SP
 +
|
 
|
 
|
 
|
 
|
Line 836: Line 961:
 
|           Light Chain  and Heavy Chain Deposition Disease||Disease||
 
|           Light Chain  and Heavy Chain Deposition Disease||Disease||
 
| ||SP
 
| ||SP
 +
|
 
|
 
|
 
|
 
|
Line 842: Line 968:
 
|'''''Plasma Cell Neoplasms with Associated Paraneoplastic Syndrome'''''||'''''Overview'''''||
 
|'''''Plasma Cell Neoplasms with Associated Paraneoplastic Syndrome'''''||'''''Overview'''''||
 
| ||SP
 
| ||SP
 +
|
 
|
 
|
 
|
 
|
Line 848: Line 975:
 
|         POEMS Syndrome||Disease||
 
|         POEMS Syndrome||Disease||
 
| ||SP
 
| ||SP
 +
|
 
|
 
|
 
|
 
|
Line 854: Line 982:
 
|         TEMPI Syndrome||Disease||
 
|         TEMPI Syndrome||Disease||
 
| ||SP
 
| ||SP
 +
|
 
|
 
|
 
|
 
|
Line 862: Line 991:
 
|SP
 
|SP
 
|PENDING
 
|PENDING
 +
|
 
|
 
|
 
|
 
|
Line 867: Line 997:
 
|Nodal Marginal Zone Lymphoma||Disease||
 
|Nodal Marginal Zone Lymphoma||Disease||
 
| ||SP
 
| ||SP
 +
|
 
|
 
|
 
|
 
|
Line 875: Line 1,006:
 
|SP
 
|SP
 
|PENDING
 
|PENDING
 +
|
 
|
 
|
 
|
 
|
Line 882: Line 1,014:
 
|SP
 
|SP
 
|PENDING
 
|PENDING
 +
|
 
|
 
|
 
|
 
|
Line 889: Line 1,022:
 
|SP
 
|SP
 
|PENDING
 
|PENDING
 +
|
 
|
 
|
 
|
 
|
Line 896: Line 1,030:
 
|SP
 
|SP
 
|PENDING
 
|PENDING
 +
|
 
|
 
|
 
|
 
|
Line 903: Line 1,038:
 
|SP
 
|SP
 
|PENDING
 
|PENDING
 +
|
 
|
 
|
 
|
 
|
Line 910: Line 1,046:
 
|SP
 
|SP
 
|PENDING
 
|PENDING
 +
|
 
|
 
|
 
|
 
|
Line 915: Line 1,052:
 
|Large B-cell Lymphoma with IRF4 Rearrangement||Disease||
 
|Large B-cell Lymphoma with IRF4 Rearrangement||Disease||
 
| ||SP
 
| ||SP
 +
|
 
|
 
|
 
|
 
|
Line 921: Line 1,059:
 
|Primary Cutaneous Follicle Centre Lymphoma||Disease||
 
|Primary Cutaneous Follicle Centre Lymphoma||Disease||
 
| ||SP
 
| ||SP
 +
|
 
|
 
|
 
|
 
|
Line 929: Line 1,068:
 
|SP
 
|SP
 
|PENDING - due 8/15/20
 
|PENDING - due 8/15/20
 +
|
 
|
 
|
 
|
 
|
Line 936: Line 1,076:
 
|SP
 
|SP
 
|PENDING - due 8/31/20
 
|PENDING - due 8/31/20
 +
|
 
|
 
|
 
|
 
|
Line 943: Line 1,084:
 
|SP
 
|SP
 
|PENDING - due 8/15/20
 
|PENDING - due 8/15/20
 +
|
 
|
 
|
 
|
 
|
Line 948: Line 1,090:
 
| || ||
 
| || ||
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 956: Line 1,099:
 
|Greg Corboy (GC)
 
|Greg Corboy (GC)
 
|PENDING
 
|PENDING
 +
|
 
|
 
|
 
|
 
|
Line 961: Line 1,105:
 
|T-cell/Histiocyte-Rich Large B-cell Lymphoma||Disease||
 
|T-cell/Histiocyte-Rich Large B-cell Lymphoma||Disease||
 
| ||GC
 
| ||GC
 +
|
 
|
 
|
 
|
 
|
Line 967: Line 1,112:
 
|Primary Diffuse Large B-cell Lymphoma of the CNS||Disease||
 
|Primary Diffuse Large B-cell Lymphoma of the CNS||Disease||
 
| ||GC
 
| ||GC
 +
|
 
|
 
|
 
|
 
|
Line 973: Line 1,119:
 
|Primary Cutaneous Diffuse Large B-cell Lymphoma, Leg Type||Disease||
 
|Primary Cutaneous Diffuse Large B-cell Lymphoma, Leg Type||Disease||
 
| ||GC
 
| ||GC
 +
|
 
|
 
|
 
|
 
|
Line 979: Line 1,126:
 
|EBV-Positive Diffuse Large B-cell Lymphoma, Not Otherwise  Specified (NOS)||Disease||
 
|EBV-Positive Diffuse Large B-cell Lymphoma, Not Otherwise  Specified (NOS)||Disease||
 
| ||GC
 
| ||GC
 +
|
 
|
 
|
 
|
 
|
Line 985: Line 1,133:
 
|EBV-Positive Mucocutaneous Ulcer||Disease||
 
|EBV-Positive Mucocutaneous Ulcer||Disease||
 
| ||GC
 
| ||GC
 +
|
 
|
 
|
 
|
 
|
Line 991: Line 1,140:
 
|Diffuse Large B-cell Lymphoma Associated with Chronic  Inflammation||Disease||
 
|Diffuse Large B-cell Lymphoma Associated with Chronic  Inflammation||Disease||
 
| ||GC
 
| ||GC
 +
|
 
|
 
|
 
|
 
|
Line 997: Line 1,147:
 
|    Fibrin-Associated  Diffuse Large B-cell Lymphoma||Disease||
 
|    Fibrin-Associated  Diffuse Large B-cell Lymphoma||Disease||
 
| ||GC
 
| ||GC
 +
|
 
|
 
|
 
|
 
|
Line 1,003: Line 1,154:
 
|Lymphomatoid Granulomatosis||Disease||
 
|Lymphomatoid Granulomatosis||Disease||
 
| ||GC
 
| ||GC
 +
|
 
|
 
|
 
|
 
|
Line 1,009: Line 1,161:
 
|Primary Mediastinal (Thymic) Large B-cell Lymphoma||Disease||
 
|Primary Mediastinal (Thymic) Large B-cell Lymphoma||Disease||
 
| ||GC
 
| ||GC
 +
|
 
|
 
|
 
|
 
|
Line 1,015: Line 1,168:
 
|Intravascular Large B-cell Lymphoma||Disease||
 
|Intravascular Large B-cell Lymphoma||Disease||
 
| ||GC
 
| ||GC
 +
|
 
|
 
|
 
|
 
|
Line 1,021: Line 1,175:
 
|ALK-Positive Large B-cell Lymphoma||Disease||
 
|ALK-Positive Large B-cell Lymphoma||Disease||
 
| ||GC
 
| ||GC
 +
|
 
|
 
|
 
|
 
|
Line 1,028: Line 1,183:
 
| ||GC
 
| ||GC
 
|Complete
 
|Complete
 +
|
 
|
 
|
 
|
 
|
Line 1,033: Line 1,189:
 
|Primary Effusion Lymphoma||Disease||
 
|Primary Effusion Lymphoma||Disease||
 
| ||GC
 
| ||GC
 +
|
 
|
 
|
 
|
 
|
Line 1,039: Line 1,196:
 
|'''''HHV8-Associated Lymphoproliferative Disorders'''''||'''''Overview'''''||
 
|'''''HHV8-Associated Lymphoproliferative Disorders'''''||'''''Overview'''''||
 
| ||GC
 
| ||GC
 +
|
 
|
 
|
 
|
 
|
Line 1,045: Line 1,203:
 
|   Multicentric Castleman  Disease||Disease||
 
|   Multicentric Castleman  Disease||Disease||
 
| ||GC
 
| ||GC
 +
|
 
|
 
|
 
|
 
|
Line 1,051: Line 1,210:
 
|   HHV8-Positive Diffuse  Large B-cell Lymphoma, Not Otherwise Specified (NOS)||Disease||
 
|   HHV8-Positive Diffuse  Large B-cell Lymphoma, Not Otherwise Specified (NOS)||Disease||
 
| ||GC
 
| ||GC
 +
|
 
|
 
|
 
|
 
|
Line 1,057: Line 1,217:
 
|   HHV8-Positive  Germinotropic Lymphoproliferative Disorder||Disease||
 
|   HHV8-Positive  Germinotropic Lymphoproliferative Disorder||Disease||
 
| ||GC
 
| ||GC
 +
|
 
|
 
|
 
|
 
|
Line 1,063: Line 1,224:
 
|Burkitt Lymphoma||Disease||
 
|Burkitt Lymphoma||Disease||
 
| ||GC
 
| ||GC
 +
|
 
|
 
|
 
|
 
|
Line 1,069: Line 1,231:
 
|Burkitt-Like Lymphoma with 11q Aberration||Disease||
 
|Burkitt-Like Lymphoma with 11q Aberration||Disease||
 
| ||GC
 
| ||GC
 +
|
 
|
 
|
 
|
 
|
Line 1,075: Line 1,238:
 
|'''''High-Grade B-cell Lymphoma'''''||'''''Overview'''''||
 
|'''''High-Grade B-cell Lymphoma'''''||'''''Overview'''''||
 
| ||GC
 
| ||GC
 +
|
 
|
 
|
 
|
 
|
Line 1,081: Line 1,245:
 
|    High-Grade B-cell  Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements||Disease||
 
|    High-Grade B-cell  Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements||Disease||
 
| ||GC
 
| ||GC
 +
|
 
|
 
|
 
|
 
|
Line 1,087: Line 1,252:
 
|    High-Grade B-cell  Lymphoma, Not Otherwise Specified (NOS)||Disease||
 
|    High-Grade B-cell  Lymphoma, Not Otherwise Specified (NOS)||Disease||
 
| ||GC
 
| ||GC
 +
|
 
|
 
|
 
|
 
|
Line 1,093: Line 1,259:
 
|B-cell Lymphoma, Unclassifiable, with Features Intermediate  Between Diffuse Large B-cell Lymphoma and Classic Hodgkin Lymphoma||Disease||
 
|B-cell Lymphoma, Unclassifiable, with Features Intermediate  Between Diffuse Large B-cell Lymphoma and Classic Hodgkin Lymphoma||Disease||
 
| ||GC
 
| ||GC
 +
|
 
|
 
|
 
|
 
|
Line 1,099: Line 1,266:
 
| || ||
 
| || ||
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,105: Line 1,273:
 
|'''''Mature T- and NK-cell Neoplasms'''''||'''''Overview'''''||
 
|'''''Mature T- and NK-cell Neoplasms'''''||'''''Overview'''''||
 
| ||Snehal Patel (SP)
 
| ||Snehal Patel (SP)
 +
|
 
|
 
|
 
|
 
|
Line 1,112: Line 1,281:
 
| ||SP
 
| ||SP
 
|PENDING
 
|PENDING
 +
|
 
|
 
|
 
|
 
|
Line 1,118: Line 1,288:
 
| ||SP
 
| ||SP
 
|PENDING
 
|PENDING
 +
|
 
|
 
|
 
|
 
|
Line 1,124: Line 1,295:
 
| ||SP
 
| ||SP
 
|PENDING
 
|PENDING
 +
|
 
|
 
|
 
|
 
|
Line 1,129: Line 1,301:
 
|Aggressive NK-cell Leukemia||Disease||
 
|Aggressive NK-cell Leukemia||Disease||
 
| ||SP
 
| ||SP
 +
|
 
|
 
|
 
|
 
|
Line 1,135: Line 1,308:
 
|'''''EBV-Positive T-cell and NK-cell Lymphoproliferative Diseases of  Childhood'''''||'''''Overview'''''||
 
|'''''EBV-Positive T-cell and NK-cell Lymphoproliferative Diseases of  Childhood'''''||'''''Overview'''''||
 
| ||SP
 
| ||SP
 +
|
 
|
 
|
 
|
 
|
Line 1,141: Line 1,315:
 
|  Systemic EBV-Positive  T-cell Lymphoma of Childhood||Disease||
 
|  Systemic EBV-Positive  T-cell Lymphoma of Childhood||Disease||
 
| ||SP
 
| ||SP
 +
|
 
|
 
|
 
|
 
|
Line 1,147: Line 1,322:
 
|   Chronic Active EBV  Infection of T- and NK-cell Type, Systemic Form||Disease||
 
|   Chronic Active EBV  Infection of T- and NK-cell Type, Systemic Form||Disease||
 
| ||SP
 
| ||SP
 +
|
 
|
 
|
 
|
 
|
Line 1,153: Line 1,329:
 
|    Hydroa  Vacciniforme-Like Lymphoproliferative Disorder||Disease||
 
|    Hydroa  Vacciniforme-Like Lymphoproliferative Disorder||Disease||
 
| ||SP
 
| ||SP
 +
|
 
|
 
|
 
|
 
|
Line 1,159: Line 1,336:
 
|    Severe Mosquito Bite  Allergy||Disease||
 
|    Severe Mosquito Bite  Allergy||Disease||
 
| ||SP
 
| ||SP
 +
|
 
|
 
|
 
|
 
|
Line 1,165: Line 1,343:
 
|Adult T-cell Leukemia/Lymphoma||Disease||
 
|Adult T-cell Leukemia/Lymphoma||Disease||
 
| ||SP
 
| ||SP
 +
|
 
|
 
|
 
|
 
|
Line 1,171: Line 1,350:
 
|Extranodal NK/T-cell Lymphoma, Nasal Type||Disease||
 
|Extranodal NK/T-cell Lymphoma, Nasal Type||Disease||
 
| ||SP
 
| ||SP
 +
|
 
|
 
|
 
|
 
|
Line 1,179: Line 1,359:
 
|SP
 
|SP
 
|PENDING
 
|PENDING
 +
|
 
|
 
|
 
|
 
|
Line 1,186: Line 1,367:
 
|SP
 
|SP
 
|PENDING
 
|PENDING
 +
|
 
|
 
|
 
|
 
|
Line 1,193: Line 1,375:
 
|SP
 
|SP
 
|PENDING
 
|PENDING
 +
|
 
|
 
|
 
|
 
|
Line 1,200: Line 1,383:
 
|SP
 
|SP
 
|PENDING
 
|PENDING
 +
|
 
|
 
|
 
|
 
|
Line 1,207: Line 1,391:
 
|SP
 
|SP
 
|PENDING
 
|PENDING
 +
|
 
|
 
|
 
|
 
|
Line 1,213: Line 1,398:
 
| ||SP
 
| ||SP
 
|PENDING
 
|PENDING
 +
|
 
|
 
|
 
|
 
|
Line 1,218: Line 1,404:
 
|Subcutaneous Panniculitis-Like T-cell Lymphoma||Disease||
 
|Subcutaneous Panniculitis-Like T-cell Lymphoma||Disease||
 
| ||SP
 
| ||SP
 +
|
 
|
 
|
 
|
 
|
Line 1,224: Line 1,411:
 
|Mycosis Fungoides||Disease||
 
|Mycosis Fungoides||Disease||
 
| ||SP
 
| ||SP
 +
|
 
|
 
|
 
|
 
|
Line 1,230: Line 1,418:
 
|Sézary Syndrome||Disease||
 
|Sézary Syndrome||Disease||
 
| ||SP
 
| ||SP
 +
|
 
|
 
|
 
|
 
|
Line 1,236: Line 1,425:
 
|'''''Primary Cutaneous CD30 Positive T-cell Lymphoproliferative  Disorders'''''||'''''Overview'''''||
 
|'''''Primary Cutaneous CD30 Positive T-cell Lymphoproliferative  Disorders'''''||'''''Overview'''''||
 
| ||SP
 
| ||SP
 +
|
 
|
 
|
 
|
 
|
Line 1,242: Line 1,432:
 
|    Lymphomatoid  Papulosis||Disease||
 
|    Lymphomatoid  Papulosis||Disease||
 
| ||SP
 
| ||SP
 +
|
 
|
 
|
 
|
 
|
Line 1,248: Line 1,439:
 
|    Primary Cutaneous  Anaplastic Large Cell Lymphoma||Disease||
 
|    Primary Cutaneous  Anaplastic Large Cell Lymphoma||Disease||
 
| ||SP
 
| ||SP
 +
|
 
|
 
|
 
|
 
|
Line 1,254: Line 1,446:
 
|'''''Primary Cutaneous Peripheral T-cell Lymphomas, Rare Subtypes'''''||'''''Overview'''''||
 
|'''''Primary Cutaneous Peripheral T-cell Lymphomas, Rare Subtypes'''''||'''''Overview'''''||
 
| ||SP
 
| ||SP
 +
|
 
|
 
|
 
|
 
|
Line 1,260: Line 1,453:
 
|     Primary Cutaneous  Gamma Delta T-cell Lymphoma||Disease||
 
|     Primary Cutaneous  Gamma Delta T-cell Lymphoma||Disease||
 
| ||SP
 
| ||SP
 +
|
 
|
 
|
 
|
 
|
Line 1,266: Line 1,460:
 
|     Primary Cutaneous  CD8+ Aggressive Epidermotropic Cytotoxic T-cell Lymphoma||Disease||
 
|     Primary Cutaneous  CD8+ Aggressive Epidermotropic Cytotoxic T-cell Lymphoma||Disease||
 
| ||SP
 
| ||SP
 +
|
 
|
 
|
 
|
 
|
Line 1,272: Line 1,467:
 
|     Primary Cutaneous  Acral CD8+ T-cell Lymphoma||Disease||
 
|     Primary Cutaneous  Acral CD8+ T-cell Lymphoma||Disease||
 
| ||SP
 
| ||SP
 +
|
 
|
 
|
 
|
 
|
Line 1,278: Line 1,474:
 
|     Primary Cutaneous  CD4+ Small/Medium T-cell Lymphoproliferative Disorder||Disease||
 
|     Primary Cutaneous  CD4+ Small/Medium T-cell Lymphoproliferative Disorder||Disease||
 
| ||SP
 
| ||SP
 +
|
 
|
 
|
 
|
 
|
Line 1,284: Line 1,481:
 
|Peripheral T-cell Lymphoma, Not Otherwise Specified (NOS)||Disease||
 
|Peripheral T-cell Lymphoma, Not Otherwise Specified (NOS)||Disease||
 
| ||SP
 
| ||SP
 +
|
 
|
 
|
 
|
 
|
Line 1,290: Line 1,488:
 
|'''''Angioimmunoblastic T-cell Lymphoma and Other Nodal Lymphomas of  T Follicular Helper Cell Origin'''''||'''''Overview'''''||
 
|'''''Angioimmunoblastic T-cell Lymphoma and Other Nodal Lymphomas of  T Follicular Helper Cell Origin'''''||'''''Overview'''''||
 
| ||SP
 
| ||SP
 +
|
 
|
 
|
 
|
 
|
Line 1,298: Line 1,497:
 
|SP
 
|SP
 
|PENDING
 
|PENDING
 +
|
 
|
 
|
 
|
 
|
Line 1,305: Line 1,505:
 
|SP
 
|SP
 
|PENDING
 
|PENDING
 +
|
 
|
 
|
 
|
 
|
Line 1,310: Line 1,511:
 
|     Nodal Peripheral  T-cell Lymphoma with T Follicular Helper Phenotype||Disease||
 
|     Nodal Peripheral  T-cell Lymphoma with T Follicular Helper Phenotype||Disease||
 
| ||SP
 
| ||SP
 +
|
 
|
 
|
 
|
 
|
Line 1,318: Line 1,520:
 
|SP
 
|SP
 
|PENDING
 
|PENDING
 +
|
 
|
 
|
 
|
 
|
Line 1,325: Line 1,528:
 
|SP
 
|SP
 
|PENDING
 
|PENDING
 +
|
 
|
 
|
 
|
 
|
Line 1,332: Line 1,536:
 
|SP
 
|SP
 
|PENDING
 
|PENDING
 +
|
 
|
 
|
 
|
 
|
Line 1,337: Line 1,542:
 
| || ||
 
| || ||
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,343: Line 1,549:
 
|'''''Hodgkin Lymphomas'''''||'''''Overview'''''||
 
|'''''Hodgkin Lymphomas'''''||'''''Overview'''''||
 
| ||Associate Editor??
 
| ||Associate Editor??
 +
|
 
|
 
|
 
|
 
|
Line 1,349: Line 1,556:
 
|Nodular Lymphocyte Predominant Hodgkin Lymphoma||Disease||
 
|Nodular Lymphocyte Predominant Hodgkin Lymphoma||Disease||
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,355: Line 1,563:
 
|'''''Classic Hodgkin Lymphoma'''''||'''''Overview'''''||
 
|'''''Classic Hodgkin Lymphoma'''''||'''''Overview'''''||
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,361: Line 1,570:
 
|    Nodular Sclerosis  Classic Hodgkin Lymphoma||Disease||
 
|    Nodular Sclerosis  Classic Hodgkin Lymphoma||Disease||
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,367: Line 1,577:
 
|    Lymphocyte-Rich  Classic Hodgkin Lymphoma||Disease||
 
|    Lymphocyte-Rich  Classic Hodgkin Lymphoma||Disease||
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,373: Line 1,584:
 
|    Mixed Cellularity  Classic Hodgkin Lymphoma||Disease||
 
|    Mixed Cellularity  Classic Hodgkin Lymphoma||Disease||
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,379: Line 1,591:
 
|    Lymphocyte-Depleted  Classic Hodgkin Lymphoma||Disease||
 
|    Lymphocyte-Depleted  Classic Hodgkin Lymphoma||Disease||
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,385: Line 1,598:
 
|'''''Immunodeficiency-Associated Lymphoproliferative Disorders'''''||'''''Overview'''''||
 
|'''''Immunodeficiency-Associated Lymphoproliferative Disorders'''''||'''''Overview'''''||
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,391: Line 1,605:
 
|Lymphomas Associated with HIV Infection||Disease||
 
|Lymphomas Associated with HIV Infection||Disease||
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,397: Line 1,612:
 
|'''''Post-Transplant Lymphoproliferative Disorders'''''||'''''Overview'''''||
 
|'''''Post-Transplant Lymphoproliferative Disorders'''''||'''''Overview'''''||
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,403: Line 1,619:
 
|    Non-Destructive  Post-Transplant Lymphoproliferative Disorders||Disease||
 
|    Non-Destructive  Post-Transplant Lymphoproliferative Disorders||Disease||
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,413: Line 1,630:
 
|
 
|
 
|PENDING
 
|PENDING
 +
|
 
|
 
|
 
|
 
|
Line 1,418: Line 1,636:
 
|'''''    Monomorphic  Post-Transplant Lymphoproliferative Disorders (B- and T/NK-cell Types)'''''||'''''Overview'''''||
 
|'''''    Monomorphic  Post-Transplant Lymphoproliferative Disorders (B- and T/NK-cell Types)'''''||'''''Overview'''''||
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,424: Line 1,643:
 
|          Monomorphic  B-cell PTLD||Disease||
 
|          Monomorphic  B-cell PTLD||Disease||
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,430: Line 1,650:
 
|          Monomorphic  T/NK-cell PTLD||Disease||
 
|          Monomorphic  T/NK-cell PTLD||Disease||
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,436: Line 1,657:
 
|    Classical Hodgkin  Lymphoma Post-Transplant Lymphoproliferative Disorder||Disease||
 
|    Classical Hodgkin  Lymphoma Post-Transplant Lymphoproliferative Disorder||Disease||
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,442: Line 1,664:
 
|Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative  Disorders||Disease||
 
|Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative  Disorders||Disease||
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,448: Line 1,671:
 
|'''''Histiocytic and Dendritic Cell Neoplasms'''''||'''''Overview'''''||
 
|'''''Histiocytic and Dendritic Cell Neoplasms'''''||'''''Overview'''''||
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,454: Line 1,678:
 
|Histiocytic Sarcoma||Disease||
 
|Histiocytic Sarcoma||Disease||
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,460: Line 1,685:
 
|'''''Tumors Derived From Langerhans Cells'''''||'''''Overview'''''||
 
|'''''Tumors Derived From Langerhans Cells'''''||'''''Overview'''''||
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,466: Line 1,692:
 
|   Langerhans Cell  Histiocytosis||Disease||
 
|   Langerhans Cell  Histiocytosis||Disease||
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,472: Line 1,699:
 
|   Langerhans Cell  Sarcoma||Disease||
 
|   Langerhans Cell  Sarcoma||Disease||
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,478: Line 1,706:
 
|Indeterminate Dendritic Cell Tumour||Disease||
 
|Indeterminate Dendritic Cell Tumour||Disease||
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,484: Line 1,713:
 
|Interdigitating Dendritic Cell Sarcoma||Disease||
 
|Interdigitating Dendritic Cell Sarcoma||Disease||
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,490: Line 1,720:
 
|Follicular Dendritic Cell Sarcoma||Disease||
 
|Follicular Dendritic Cell Sarcoma||Disease||
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,496: Line 1,727:
 
|    Inflammatory  Pseudotumor-Like Follicular/Fibroblastic Dendritic Cell Sarcoma||Disease||
 
|    Inflammatory  Pseudotumor-Like Follicular/Fibroblastic Dendritic Cell Sarcoma||Disease||
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,502: Line 1,734:
 
|Fibroblastic Reticular Cell Tumor||Disease||
 
|Fibroblastic Reticular Cell Tumor||Disease||
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,508: Line 1,741:
 
|Disseminated Juvenile Xanthogranuloma||Disease||
 
|Disseminated Juvenile Xanthogranuloma||Disease||
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,514: Line 1,748:
 
|Erdheim-Chester Disease||Disease||
 
|Erdheim-Chester Disease||Disease||
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,520: Line 1,755:
 
| || ||
 
| || ||
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,526: Line 1,762:
 
| || ||
 
| || ||
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,532: Line 1,769:
 
| || ||
 
| || ||
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,538: Line 1,776:
 
| || ||
 
| || ||
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,544: Line 1,783:
 
| || ||
 
| || ||
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,550: Line 1,790:
 
| || ||
 
| || ||
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,556: Line 1,797:
 
| || ||
 
| || ||
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,562: Line 1,804:
 
| || ||
 
| || ||
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,568: Line 1,811:
 
| || ||
 
| || ||
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,574: Line 1,818:
 
| || ||
 
| || ||
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,580: Line 1,825:
 
| || ||
 
| || ||
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,586: Line 1,832:
 
| || ||
 
| || ||
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,592: Line 1,839:
 
| || ||
 
| || ||
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,598: Line 1,846:
 
| || ||
 
| || ||
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,604: Line 1,853:
 
| || ||
 
| || ||
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,610: Line 1,860:
 
| || ||
 
| || ||
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,616: Line 1,867:
 
| || ||
 
| || ||
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,622: Line 1,874:
 
| || ||
 
| || ||
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,628: Line 1,881:
 
| || ||
 
| || ||
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,634: Line 1,888:
 
| || ||
 
| || ||
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|

Revision as of 13:05, 7 August 2020

WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues Content
Disease Page Type Author Date Assigned to Author (Target Completion Date) Associate Editor Author Content Pending or Complete (Date Completed) Date Completed by Author Editor Reviewed (Date of Last Review) Notes
Myeloproliferative Neoplasms (MPN) Overview Mark Evans (trainee), Fabiola Quintero-Rivera Fabiola Quintero-Rivera (FQR) PENDING
    Chronic Myeloid Leukemia (CML), BCR-ABL1-Positive Disease Mark Evans (trainee)+Jack Reid (trainee)+Fabiola Quintero-Rivera FQR Complete
    Chronic Neutrophilic Leukemia (CNL) Disease Anamaria Munteanu (trainee)+Fabiola Quintero-Rivera FQR PENDING
    Polycythaemia Vera (PV) Disease Gokce A. Toruner FQR PENDING
    Primary Myelofibrosis (PMF) Disease T. Niroshi Senaratne FQR PENDING
    Essential Thrombocythaemia (ET) Disease Rebecca Smith (trainee) + faculty TBD FQR PENDING
    Chronic Eosinophilic Leukemia, Not Otherwise Specified Disease Mark Evans (trainee), Fabiola Quintero-Rivera FQR PENDING
    Myeloproliferative Neoplasm (MPN), Unclassifiable Disease Mark Evans (trainee)+ Fabiola Quintero-Rivera FQR PENDING
Mastocytosis Overview FQR
    Cutaneous Mastocytosis Disease Thuy Phung FQR PENDING
    Systemic Mastocytosis Disease Shashi Shetty FQR PENDING
    Mast Cell Sarcoma Disease Thuy Phung FQR PENDING
Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of PDGFRA, PDGFRB or FGFR1, or with PCM1-JAK2 Overview Daynna J.Wolff FQR PENDING
    Myeloid/Lymphoid Neoplasms with PDGFRA Rearrangement Disease Jay Alden (trainee) +Daynna J.Wolff FQR Complete
    Myeloid/Lymphoid Neoplasms with PDGFRB Rearrangement Disease Christopher Sullivan (trainee) + Daynna J.Wolff FQR Complete
    Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement Disease Yanna Ding FQR Complete
    Myeloid/Lymphoid Neoplasms with PCM1-JAK2 Disease Jessica Snider (trainee) + Daynna J.Wolff FQR Complete
Myeloid/Lymphoid Neoplasms with ETV6-JAK2 Disease Lauren R. Crowson (trainee)-Hindman + Daynna J. Wolff FQR Complete NON-WHO ENTITY
Myeloid/Lymphoid Neoplasms with BCR-JAK2 Disease Lauren R. Crowson (trainee) + Daynna J. Wolff FQR Complete NON-WHO ENTITY
Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) Overview Linsheng Zhang FQR Complete
    Chronic Myelomonocytic Leukemia (CMML) Disease Linsheng Zhang FQR Complete
    Atypical Chronic Myeloid Leukemia (aCML), BCR-ABL1 Negative Disease Linsheng Zhang FQR Complete
    Juvenile Myelomonocytic Leukemia (JMML) Disease Sarah Rapisardo FQR PENDING
    Myelodysplastic/Myeloproliferative Neoplasms with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T) Disease Anamaria Munteanu (trainee)+Fabiola Quintero-Rivera FQR PENDING
    Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN), Unclassifiable Disease Ruth MacKinnon FQR PENDING
Myelodysplastic Syndromes (MDS) Overview Teresa Smolarek? FQR
    Myelodysplastic Syndrome (MDS) with Single Lineage Dysplasia Disease Xiaoli Du(trainee) +Teresa Smolarek FQR PENDING
    Myelodysplastic Syndrome with Ring Sideroblasts (MDS-RS) Disease Xiaolin Hu(trainee)+Teresa Smolarek FQR Complete
    Myelodysplastic Syndrome with Ring Sideroblasts and Multilineage Dysplasia Disease Xiaolin Hu(trainee)+Teresa Smolarek FQR Complete
    Myelodysplastic syndrome with multilineage dysplasiaMyelodysplastic Syndrome (MDS) with Multilineage Dysplasia Disease Xiaoli Du(trainee)+Teresa Smolarek FQR PENDING
    Myelodysplastic Syndrome (MDS) with Excess Blasts Disease Xiaoli Du(trainee)+Teresa Smolarek FQR PENDING
    Myelodysplastic Syndrome (MDS) with Isolated del(5q) Disease Xiaolin Hu(trainee)+Teresa Smolarek FQR Complete
    Myelodysplastic Syndrome (MDS), Unclassifiable Disease Xiaolin Hu(trainee)+Teresa Smolarek FQR PENDING
    Refractory Cytopenia of Childhood Disease Xiaoli Du(trainee)+Teresa Smolarek FQR PENDING
Acute Myeloid Leukemia (AML) and Related Precursor Neoplasms Overview Daynna Wolff+Daniel Butler (Path Resident) Jennelle Hodge (JH)/ Malini Sathanoori (MS) Complete
Myeloid Neoplasms with Germline Predisposition Overview Ying Zou JH / MS Complete
    Acute Myeloid Leukaemia with Germline CEBPA Mutation Disease Daynna Wolff+Matthew Kilpatrick (Path Resident) JH / MS PENDING
    Myeloid Neoplasms with Germline DDX41 Mutation Disease Fei Yang JH / MS PENDING
    Myeloid Neoplasms with Germline RUNX1 Mutation Disease Malini Sathanoori JH / MS PENDING
    Myeloid Neoplasms with Germline ANKRD26 Mutation Disease Fei Yang JH / MS PENDING
    Myeloid Neoplasms with Germline ETV6 Mutation Disease Ying Zou JH / MS Complete
    Myeloid Neoplasms with Germline GATA2 Mutation Disease Daynna Wolff+ Alexandria Avery (Path Resident) JH / MS Complete
Acute Myeloid Leukemia (AML) with Recurrent Genetic Abnormalities Overview Daynna Wolff+ Dan Wang (trainee) JH / MS Complete
    Acute Myeloid Leukemia (AML) with t(8;21)(q22;q22.1); RUNX1-RUNX1T1 Disease Christine Bryke JH / MS Complete
    Acute Myeloid Leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 Disease Christine Bryke JH / MS Complete
    Acute Promyelocytic Leukemia (APL) with PML-RARA Disease Shashi Shetty JH / MS Complete
    Acute Myeloid Leukemia (AML) with t(9;11)(p21.3;q23.3); KMT2A-MLLT3 Disease Shashi Shetty JH / MS Complete
    Acute Myeloid Leukemia (AML) with t(6;9)(p23;q34.1); DEK-NUP214 Disease Jennelle Hodge JH / MS Complete
    Acute Myeloid Leukemia (AML) with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2);GATA2, MECOM Disease Gordana Raca JH / MS Complete Need permission for figure? Update WHO?
    Acute Myeloid Leukemia (AML) Megakaryoblastic with t(1;22)(p13.3;q13.1);RBM15-MKL1 Disease Jennelle Hodge JH / MS Complete
    Acute Myeloid Leukemia (AML) with BCR-ABL1 Disease Kay Weng Choy + Greg Conboy (Monash Health) JH / MS Complete
    Acute Myeloid Leukemia (AML) with Mutated NPM1 Disease Xinjie Xu+Kay Weng Choy + Greg Conboy (Monash Health) JH / MS Complete Add WHO reference
    Acute Myeloid Leukemia (AML) with Biallelic Mutations of CEBPA Disease Paul deFazio, MSc + Greg Conboy (Monash Health) JH / MS Complete
    Acute Myeloid Leukemia (AML) with Mutated RUNX1 Disease Daynna Wolff+Iris Martin (Path Resident) JH / MS Complete
Acute Myeloid Leukemia (AML) with Myelodysplasia-Related Changes Disease Fei Yang JH / MS Complete
Therapy-Related Myeloid Neoplasms Disease Shashi Shetty + Shawn A. Silver (resident) JH / MS Complete Check reference format
Acute Myeloid Leukemia (AML), Not Otherwise Specified Overview Anwar Iqbal JH / MS Complete
    Acute Myeloid Leukemia (AML) with Minimal Differentiation Disease Fabiola Quintero-Rivera and Celeste Eno (fellow) JH / MS Complete
   Acute Myeloid Leukemia (AML) without Maturation Disease Jennelle Hodge JH / MS Complete
    Acute Myeloid Leukemia (AML) with Maturation Disease Jennelle Hodge JH / MS Complete
    Acute Myelomonocytic Leukemia Disease Fei Yang JH / MS Complete
    Acute Monoblastic and Monocytic Leukemia Disease Fei Yang JH / MS Complete
    Pure Erythroid Leukemia Disease Ash Yenamandra JH / MS Complete
    Acute Megakaryoblastic Leukemia (AMKL) Disease Fei Yang JH / MS Complete
    Acute Basophilic Leukemia Disease Ash Yenamandra JH / MS Complete
    Acute Panmyelosis with Myelofibrosis Disease Ying Zou and Jialing Huang (MGP fellow) JH / MS Complete
Myeloid Sarcoma Disease Fabiola Quintero-Rivera JH / MS Complete
Myeloid Proliferations Associated with Down Syndrome Overview Patty Greipp JH / MS Complete Need permission for figure?
    Transient Abnormal Myelopoiesis (TAM) Associated with Down Syndrome Disease Linda Cooley JH / MS Complete
    Myeloid Leukemia Associated with Down Syndrome Disease Linda Cooley JH / MS Complete
Blastic Plasmacytoid Dendritic Cell Neoplasm Disease Daynna Wolff+Hao Liu (Path Resident) JH / MS Complete
Acute Leukemias of Ambiguous Lineage Overview Hui Chen/ Jennelle Hodge JH / MS Complete
    Acute Undifferentiated Leukemia Disease Shashi Shetty + Amelia Nakanishi (resident) JH / MS Complete Check reference format
    Mixed Phenotype Acute Leukemia (MPAL) with t(9;22)(q34.1;q11.2); BCR-ABL1 Disease Tracy Tucker JH / MS Complete
    Mixed Phenotype Acute Leukemia (MPAL) with t(v;11q23.3); KMT2A Rearranged Disease Tracy Tucker JH / MS Complete
    Mixed Phenotype Acute Leukemia (MPAL), B/Myeloid, Not Otherwise Specified Disease Shashi Shetty + Priyatharsini Nirmalanantham (resident) JH / MS Complete Check reference format
    Mixed Phenotype Acute Leukemia (MPAL), T/Myeloid, Not Otherwise Specified Disease Fabiola Quintero-Rivera JH / MS Complete
    ??Mixed-Phenotype Acute Leukaemia, Not Otherwise Specified (NOS), Rare Types Disease JH / MS ??
    ??Acute Leukaemias of Ambiguous Lineage, Not Otherwise Specified (NOS) Disease JH / MS ??
Acute Myeloid Leukemia (AML) with Mutated FLT3 Disease Kay Weng Choy + Greg Conboy (Monash Health) JH / MS Complete NON-WHO ENTITY
Acute Myeloid Leukemia (AML) with NUP214-ABL1 Disease Daynna Wolff+Jessica Snider (Path Resident) JH / MS PENDING NON-WHO ENTITY
Acute Myeloid Leukemia (AML) with t(4;12)(q12;p13); CHIC2-ETV6 Disease Daynna Wolff+ Paige Woodham (Path Resident) JH / MS PENDING NON-WHO ENTITY
Precursor Lymphoid Neoplasms Overview Yassmine Akkari (YA)
B-Lymphoblastic Leukemia/Lymphoma with Recurrent Genetic Abnormalities Overview YA
    B-Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1     Disease YA
    B-Lymphoblastic Leukemia/Lymphoma with t(v;11q23.3); KMT2A-Rearranged Disease Yassmine Akkari+Nicolas Millan (trainee) YA PENDING
    B-Lymphoblastic Leukemia/Lymphoma with t(12;21)(p13.2;q22.1); ETV6-RUNX1 Disease YA
    B-Lymphoblastic Leukemia/Lymphoma with Hyperdiploidy Disease YA
    B-Lymphoblastic Leukemia/Lymphoma with Hypodiploidy Disease Ashwini Yenamandra +

Lisa Smith + Yassmine Akkari

YA Complete
    B-Lymphoblastic Leukemia/Lymphoma with t(5;14)(q31.1;q32.1); IGH/IL3 Disease YA
    B-Lymphoblastic Leukemia/Lymphoma with t(1;19)(q23;p13.3); TCF3-PBX1 Disease YA
    B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like Disease Mark G. Evans + Fabiola Quintero-Rivera YA Complete
    B-Lymphoblastic Leukemia/Lymphoma with iAMP21 Disease YA
    B-Lymphoblastic Leukemia/Lymphoma, Not Otherwise Specified Disease YA
T-Lymphoblastic Leukemia/Lymphoma Overview YA
Early T-Cell Precursor Lymphoblastic Leukemia Disease YA
NK-Lymphoblastic Leukemia/Lymphoma Disease YA
B-Lymphoblastic Leukemia/Lymphoma with ZNF384 Rearrangements Disease Helene Bruyere YA PENDING NON-WHO ENTITY
Mature B-Cell Neoplasms Overview Snehal Patel (SP)
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Disease Honey Reddi SP PENDING
       Monoclonal B-cell Lymphocytosis Disease Honey Reddi SP PENDING
B-cell Prolymphocytic Leukemia Disease Honey Reddi SP PENDING
Splenic Marginal Zone Lymphoma Disease Snehal Patel SP Complete Malini to review
Hairy Cell Leukemia Disease Snehal Patel SP Complete Malini to review
Splenic B-cell Lymphoma/Leukemia, Unclassifiable Overview Snehal Patel SP Complete Malini to review
    Splenic Diffuse Red Pulp Small B-cell Lymphoma Disease Snehal Patel SP Complete Malini to review
    Hairy Cell Leukemia Variant Disease Snehal Patel SP Complete Malini to review
Lymphoplasmacytic Lymphoma Disease Honey Reddi SP PENDING
   Waldenstrom Macroglobulinemia Disease Honey Reddi SP PENDING
IgM Monoclonal Gammopathy of Undetermined Significance Disease SP
Heavy Chain Diseases Overview SP
    Mu Heavy Chain Disease Disease SP
   Gamma Heavy Chain Disease Disease SP
    Alpha Heavy Chain Disease Disease SP
Plasma Cell Neoplasms Overview Zhenya Tang SP PENDING
   Non-IgM Monoclonal Gammopathy of Undetermined Significance Disease Zhenya Tang SP PENDING
    Plasma Cell Myeloma Disease Zhenya Tang/Huang Mo (trainee) SP PENDING
    Plasma Cell Myeloma Variants Disease Zhenya Tang SP PENDING
    Plasmacytoma Disease Zhenya Tang SP PENDING
    Monoclonal Immunoglobulin Deposition Diseases Overview SP
           Primary Amyloidosis Disease SP
           Light Chain and Heavy Chain Deposition Disease Disease SP
Plasma Cell Neoplasms with Associated Paraneoplastic Syndrome Overview SP
         POEMS Syndrome Disease SP
         TEMPI Syndrome Disease SP
Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma) Disease Zhenya Tang & Trainee SP PENDING
Nodal Marginal Zone Lymphoma Disease SP
    Paediatric Nodal Marginal Zone Lymphoma Disease Ruthann Pfau, Kathleen Schieffer (trainee) SP PENDING
Follicular Lymphoma Disease Ruthann Pfau SP PENDING
    Testicular Follicular Lymphoma Disease Ruthann Pfau SP PENDING
    In Situ Follicular Neoplasia Disease Ruthann Pfau SP PENDING
    Duodenal-Type Follicular Lymphoma Disease Ruthann Pfau SP PENDING
Paediatric-Type Follicular Lymphoma Disease Ruthann Pfau, Kathleen Schieffer (trainee) SP PENDING
Large B-cell Lymphoma with IRF4 Rearrangement Disease SP
Primary Cutaneous Follicle Centre Lymphoma Disease SP
Mantle Cell Lymphoma Disease Mahsa Khanlari SP PENDING - due 8/15/20
    Leukemic Non-Nodal Mantle Cell Lymphoma Disease Mahsa Khanlari SP PENDING - due 8/31/20
    In Situ Mantle Cell Neoplasia Disease Mahsa Khanlari SP PENDING - due 8/15/20
Diffuse Large B-cell Lymphoma, Not Otherwise Specified Disease Ashwini Yenamandra Greg Corboy (GC) PENDING
T-cell/Histiocyte-Rich Large B-cell Lymphoma Disease GC
Primary Diffuse Large B-cell Lymphoma of the CNS Disease GC
Primary Cutaneous Diffuse Large B-cell Lymphoma, Leg Type Disease GC
EBV-Positive Diffuse Large B-cell Lymphoma, Not Otherwise Specified (NOS) Disease GC
EBV-Positive Mucocutaneous Ulcer Disease GC
Diffuse Large B-cell Lymphoma Associated with Chronic Inflammation Disease GC
    Fibrin-Associated Diffuse Large B-cell Lymphoma Disease GC
Lymphomatoid Granulomatosis Disease GC
Primary Mediastinal (Thymic) Large B-cell Lymphoma Disease GC
Intravascular Large B-cell Lymphoma Disease GC
ALK-Positive Large B-cell Lymphoma Disease GC
Plasmablastic Lymphoma Disease Mark Evans (trainee), Fabiola Quintero-Rivera GC Complete
Primary Effusion Lymphoma Disease GC
HHV8-Associated Lymphoproliferative Disorders Overview GC
   Multicentric Castleman Disease Disease GC
   HHV8-Positive Diffuse Large B-cell Lymphoma, Not Otherwise Specified (NOS) Disease GC
   HHV8-Positive Germinotropic Lymphoproliferative Disorder Disease GC
Burkitt Lymphoma Disease GC
Burkitt-Like Lymphoma with 11q Aberration Disease GC
High-Grade B-cell Lymphoma Overview GC
    High-Grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements Disease GC
    High-Grade B-cell Lymphoma, Not Otherwise Specified (NOS) Disease GC
B-cell Lymphoma, Unclassifiable, with Features Intermediate Between Diffuse Large B-cell Lymphoma and Classic Hodgkin Lymphoma Disease GC
Mature T- and NK-cell Neoplasms Overview Snehal Patel (SP)
T-cell Prolymphocytic Leukemia Disease Michelle Don SP PENDING
T-cell Large Granular Lymphocytic Leukemia Disease Michelle Don SP PENDING
Chronic Lymphoproliferative Disorder of NK Cells Disease Michelle Don SP PENDING
Aggressive NK-cell Leukemia Disease SP
EBV-Positive T-cell and NK-cell Lymphoproliferative Diseases of Childhood Overview SP
  Systemic EBV-Positive T-cell Lymphoma of Childhood Disease SP
   Chronic Active EBV Infection of T- and NK-cell Type, Systemic Form Disease SP
    Hydroa Vacciniforme-Like Lymphoproliferative Disorder Disease SP
    Severe Mosquito Bite Allergy Disease SP
Adult T-cell Leukemia/Lymphoma Disease SP
Extranodal NK/T-cell Lymphoma, Nasal Type Disease SP
Intestinal T-cell Lymphoma Overview Sumire Kitahara, Derick Okwan (trainee) SP PENDING
    Enteropathy-Associated T-cell Lymphoma Disease Sumire Kitahara, Derick Okwan (trainee) SP PENDING
     Monomorphic Epitheliotropic Intestinal T-cell Lymphoma Disease Sumire Kitahara SP PENDING
     Intestinal T-cell Lymphoma, Not Otherwise Specified (NOS) Disease Sumire Kitahara, Derick Okwan (trainee) SP PENDING
    Indolent T-cell Lymphoproliferative Disorder of the Gastrointestinal Tract Disease Sumire Kitahara, Derick Okwan (trainee) SP PENDING
Hepatosplenic T-cell Lymphoma Disease Michelle Don SP PENDING
Subcutaneous Panniculitis-Like T-cell Lymphoma Disease SP
Mycosis Fungoides Disease SP
Sézary Syndrome Disease SP
Primary Cutaneous CD30 Positive T-cell Lymphoproliferative Disorders Overview SP
    Lymphomatoid Papulosis Disease SP
    Primary Cutaneous Anaplastic Large Cell Lymphoma Disease SP
Primary Cutaneous Peripheral T-cell Lymphomas, Rare Subtypes Overview SP
     Primary Cutaneous Gamma Delta T-cell Lymphoma Disease SP
     Primary Cutaneous CD8+ Aggressive Epidermotropic Cytotoxic T-cell Lymphoma Disease SP
     Primary Cutaneous Acral CD8+ T-cell Lymphoma Disease SP
     Primary Cutaneous CD4+ Small/Medium T-cell Lymphoproliferative Disorder Disease SP
Peripheral T-cell Lymphoma, Not Otherwise Specified (NOS) Disease SP
Angioimmunoblastic T-cell Lymphoma and Other Nodal Lymphomas of T Follicular Helper Cell Origin Overview SP
     Angioimmunoblastic T-cell Lymphoma Disease Ruthann Pfau, Sara Akhavanfard (trainee) SP PENDING
    Follicular T-cell Lymphoma Disease Ruthann Pfau, Sara Akhavanfard (trainee) SP PENDING
     Nodal Peripheral T-cell Lymphoma with T Follicular Helper Phenotype Disease SP
Anaplastic Large Cell Lymphoma, ALK-Positive Disease Sumire Kitahara SP PENDING
Anaplastic Large Cell Lymphoma, ALK-Negative Disease Sumire Kitahara SP PENDING
Breast Implant-Associated Anaplastic Large Cell Lymphoma Disease Sumire Kitahara SP PENDING
Hodgkin Lymphomas Overview Associate Editor??
Nodular Lymphocyte Predominant Hodgkin Lymphoma Disease
Classic Hodgkin Lymphoma Overview
    Nodular Sclerosis Classic Hodgkin Lymphoma Disease
    Lymphocyte-Rich Classic Hodgkin Lymphoma Disease
    Mixed Cellularity Classic Hodgkin Lymphoma Disease
    Lymphocyte-Depleted Classic Hodgkin Lymphoma Disease
Immunodeficiency-Associated Lymphoproliferative Disorders Overview
Lymphomas Associated with HIV Infection Disease
Post-Transplant Lymphoproliferative Disorders Overview
    Non-Destructive Post-Transplant Lymphoproliferative Disorders Disease
    Polymorphic Post-Transplant Lymphoproliferative Disorders Disease Anna Shestakova (trainee)+,

Fabiola Quintero-Rivera

PENDING
    Monomorphic Post-Transplant Lymphoproliferative Disorders (B- and T/NK-cell Types) Overview
          Monomorphic B-cell PTLD Disease
          Monomorphic T/NK-cell PTLD Disease
    Classical Hodgkin Lymphoma Post-Transplant Lymphoproliferative Disorder Disease
Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorders Disease
Histiocytic and Dendritic Cell Neoplasms Overview
Histiocytic Sarcoma Disease
Tumors Derived From Langerhans Cells Overview
   Langerhans Cell Histiocytosis Disease
   Langerhans Cell Sarcoma Disease
Indeterminate Dendritic Cell Tumour Disease
Interdigitating Dendritic Cell Sarcoma Disease
Follicular Dendritic Cell Sarcoma Disease
    Inflammatory Pseudotumor-Like Follicular/Fibroblastic Dendritic Cell Sarcoma Disease
Fibroblastic Reticular Cell Tumor Disease
Disseminated Juvenile Xanthogranuloma Disease
Erdheim-Chester Disease Disease
Gene-Specific Pages
Gene Author Associate Editor Author Content

(Pending or Complete)

Editor Reviewed (Date) Notes
BCR Brian Davis Complete (8/10/18)
ABL1 Brian Davis Complete (4/16/19)
RUNX1 Brian Davis Complete (6/9/19)
RUNX1T1 Brian Davis Complete (5/23/19)
MYH11 Brian Davis Complete (8/6/18)
FLT3 Kay Weng Choy Complete (
NPM1 Kay Weng Choy Complete (
TP53 Kay Weng Choy Complete (
DNMT3A Kay Weng Choy Complete (
CEBPA Gordana Complete (
IDH1 Paul De Fazio Complete (
IDH2 Paul De Fazio Complete (
PML Brian Davis Complete (12/5/18)
RARA Brian Davis Complete (8/3/18)
ETV6 Brian Davis Complete (6/9/19)
KIT Brian Davis Complete (10/1/18)
CBFB Brian Davis Complete (8/2/18)
GATA2 Kay Weng Choy Complete (
PTEN Beth Pitel Pending
MLTT3
MECOM Brian Davis Pending
FGFR1(FLT2) Brian Davis Pending
KMT2A
DEK
NUP214
RBM15
MKL1
DDX41
ANKRD26
CUX1
TET2
EZH2
FOXP1
MYC
JAK2
WT1
CBL
NF1
SUZ12
ERG
EST2
RPS14
RB1
MPL
CHGA
CDH1
SRSF2
DNMT1
PRDX2
ASXL1
MN1
SF3A1
EP300
JARID2
Retrieved from "https://ccga.io/index.php?title=Volunteer_Assignments_and_Opportunities&oldid=8657"